{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"154"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"25"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"Outside China: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"100"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"29"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Outside China: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"65"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"48"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"113"}],"units":"Participants"}],"title":"Outside China: Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"31"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"32"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"title":"Outside China: Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"71"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"31"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"102"}],"units":"Participants"}],"title":"Outside China: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"35"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"title":"Mainland China: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"22"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"1"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"Mainland China: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"10"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"title":"Mainland China: Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"4"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Mainland China: Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"}],"title":"Measurable"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"}],"title":"Not measurable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Mainland China: End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"225"},{"groupId":"OG002","value":"217"}],"units":"Participants"}],"description":"BRAF V600 status from ctDNA was classified as follows; measurable: participants with detectable ctDNA had measurable BRAF V600 tumor biomarker alterations and not measurable: participants with detectable ctDNA did not have measurable BRAF V600 biomarker alterations or overall ctDNA was not detectable. The number of participants as per their BRAF V600 status from ctDNA (measurable and not measurable) have been reported in this outcome measure. In this outcome measure, data is presented for participants outside China and Mainland China participants.","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Phase 3: Arm A [EC]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"Phase 3: Arm B [EC + mFOLFOX6]"},{"description":"Participants received standard of care (SOC) chemotherapy per Investigator's choice: mFOLFOX6 with or without bevacizumab or FOLFOXIRI with or without bevacizumab or CAPOX with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. mFOLFOX6 (28-day Cycle): fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W; FOLFOXIRI (28-day Cycle): fluorouracil 2400 or 3200 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W (per local standard of care); leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 165 mg/m\\^2 as IV infusion for 90 minutes Q2W; CAPOX (21-day Cycle): capecitabine 1000 mg/m\\^2 oral tablet twice daily on Days 1-14 and oxaliplatin 130 mg/m\\^2 IV infusion for 120 minutes Q3W.","id":"OG002","title":"Phase 3: Arm C [Standard of Care Chemotherapy, Control Arm]"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The biomarker analysis set included all participants who were in the safety set and who had at least 1 of the pharmacodynamics or biomarkers evaluated at pre and/or post dose. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and \"Number Analyzed\" signifies participants evaluable for specified rows. All Participants under \"Overall Number of Participants Analyzed\" contributed data to the table but may not have data evaluable for each row.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15, Cycle 7 Day 1 and End of Treatment (anytime till maximum of 37.25 months)","title":"Phase 3: Number of Participants According to B-Raf Serine/Threonine-Protein Kinase (BRAF) Valine 600 (V600) Status From ctDNA","type":"SECONDARY","unitOfMeasure":"Participants"}